Cocrystal Pharma Inc., of Bothell, Wash., said its stock began trading this week under the new symbol COCP, marking the completion of its merger with Biozone Pharmaceuticals Inc., of Englewood Cliffs, N.J. The company is developing antiviral programs, targeting hepatitis C virus, influenza, the human rhinovirus, dengue virus and the norovirus.